Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says - 2Make your choice for the PS5 game that you love playing with companions!
- 3Improving as a Pioneer: Examples from My Vocation
- 4Day to day Temporary Positions That Compensate Fairly in the US
- 5Etymological Experiences on the Wireless transmissions: A Survey of \Learning in a hurry\ Language Web recording
- ‘Inoculation’ helps people spot political deepfakes, study finds
- 4 Famous Attractions at Disneyland
- Zelensky warns of imminent massive Russian attack on Ukraine
- UAE recalls some Nestle infant formula products, Qatar warns consumers
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- 4 Excellent Remote Headphones of 2024
- Grasping the Qualifications Among Separation and Dissolution
- Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
